A new study published in the journal EMBO Molecular Medicine describes the success of a new experimental peptide in animals that is known to inhibit receptors that cause chronic neuropathic pain,media reported. The study, led by the University of Copenhagen, is currently conducting the first human trials.
“We have developed a new way to treat chronic pain,” said study co-author Kenneth Lindegaard Madsen. That is, it does not affect the general neural signals, but only the neurological changes caused by the disease. “
It is estimated that nearly 10% of the world’s population suffers from some kind of chronic neuropathic pain. The pain is caused by disease or physical sensory damage to the nervous system, which is known to be difficult to treat, and the drugs currently available include opioids or anticonvulsants such as gabadin, although they can have side effects.
The innovation in the new study is a peptide called Tat-P4-(C5) 2. In the past, experimental treatment sparing of neuropaths was usually done by inhibiting neural pathways, but the side effects were often obvious due to the lack of specific targeted sex in treatment. The new peptides developed by the team show the effects of a receptor that may only inhibit specific, damaged, over-sensitive receptors — causing neuropathic pain in patients.
Kenneth Lindegaard Madsen says they have been studying this for more than a decade, from understanding biology, inventing and designing the compound to describing its role in animals, its effects on their behavior, and the elimination of pain.
The newly published study describes the results of peptides simulating neuropathic pain in animal models. Experiments have shown that the treatment has succeeded in reducing the pain response without affecting the wider nervous system.
“This compound is very effective, and we don’t see any side effects,” explains Kenneth Lindegaard Madsen. “We can use this peptide in mouse models and get complete pain relief in these mice without the sleeping effects specific to existing analgesic drugs.” “
Human clinical trials are currently under way to test the safety of the new compound before testing its efficacy. In addition, researchers are patenting the compound and plan to commercialize it ahead of a lengthy human clinical trial process.
The study was published in EMBO Molecular Medicine.